arrow
H

Hang Quach

University of Melbourne
H指数:39
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma

MAIA虚弱亚组分析:在移植不适用的 newly diagnosed myeloma 患者中使用达拉珠单抗联合来那度胺/地塞米松的长-term随访

Leukemia
IF13.4
2026-10-060
OAAI
Selinexor plus lenalidomide versus lenalidomide alone as maintenance therapy after autologous haematopoietic stem cell transplantation in newly diagnosed multiple myeloma: Results of the phase 3 ALLG MM23 (SeaLAND) trial

塞利尼索联合来那度胺与单用来那度胺作为自体造血干细胞移植后新诊断多发性骨髓瘤的维持治疗:ALLG MM23(SeaLAND)III期试验结果

2026-09-230
PRE
Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups

慢性淋巴细胞白血病初始免疫化疗后的来那度胺维持治疗——ALLG和FILO国际III期CLL6研究RESIDUUM部分的最终分析

2026-09-210
OAAI
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis

达拉妥木单抗、来那度胺和地塞米松在移植不适宜的新诊断多发性骨髓瘤中的应用:MAIA最终生存分析

Leukemia
IF13.4
2026-08-240
OA
Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO

伊沙佐米单抗皮下注射联合卡非佐米和地塞米松治疗复发/难治性多发性骨髓瘤的疗效与安全性:IZALCO II期研究结果

2025-12-270
OAAI
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab

用Talquetamab和Teclistamab双重靶向髓外骨髓瘤

2025-12-012
PRE
No benefit from daratumumab, bortezomib and dexamethasone (D-Vd) in real-world patients with functional high-risk multiple myeloma: A report from the Myeloma and Related Diseases Registry

达拉妥单抗、硼替佐米和地塞米松(D-Vd)在功能高危多发性骨髓瘤的真实世界患者中无获益:来自骨髓瘤及相关疾病登记研究的报告

2025-11-080
PRE
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial

患者报告的结果:比较belantamab mafodotin联合pomalidomide和地塞米松与 bortezomib联合pomalidomide和地塞米松在复发或难治性多发性骨髓瘤患者中的疗效(DREAMM-8):一项III期、开放标签、随机对照试验

2025-11-030
PRE
New Zealand multiple myeloma patients demonstrate inferior outcomes when compared to Australian counterparts – a retrospective cohort study from the Myeloma and Related Diseases Registry (MRDR).

新西兰多发性骨髓瘤患者与澳大利亚同类患者相比,结局较差——一项来自骨髓瘤及相关疾病登记系统(MRDR)的回顾性队列研究。

2025-10-200
OAAI
Real-world comparison of treatment outcomes for multiple myeloma in elderly transplant ineligible patients receiving first-line VRd, Rd and VCd: Results from the Australian and New Zealand Myeloma and Related Diseases Registry

真实世界中老年不适合移植的多发性骨髓瘤患者接受一线VRd、Rd和VCd治疗结局的比较:澳大利亚和新西兰骨髓瘤及相关疾病登记研究的结果

2025-08-090
OAAI
Modification of Belantamab Mafodotin Dosing to Balance Efficacy and Tolerability in the DREAMM-7 and DREAMM-8 Trials

在DREAMM-7和DREAMM-8试验中调整Belantamab Mafodotin给药剂量以平衡疗效和耐受性

2025-08-070
OAAI
Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular Events

Belantamab Mafodotin相关眼部事件的临床管理实用指南

2025-07-280
OAAI
Real-World Use of carfilzomib-lenalidomide-dexamethasone (KRd) and carfilzomib-dexamethasone (Kd) in Relapsed/Refractory Multiple Myeloma in the Asia Pacific Region: A Prospective Multicenter Observational Study

亚太地区复发/难治性多发性骨髓瘤中卡非佐米-来那度胺-地塞米松(KRd)和卡非佐米-地塞米松(Kd)的真实世界应用:一项前瞻性多中心观察性研究

2025-05-070
OAAI
Health-Related Quality of Life in Patients With Relapsed/Refractory Multiple Myeloma Treated With Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone: An Analysis of Patient-Reported Outcomes From the Phase 3 CANDOR Trial

与健康相关的生活质量:在复发/难治性多发性骨髓瘤患者中使用卡非佐米、地塞米松和达雷木单抗治疗与卡非佐米和地塞米松治疗的比较:基于CANDOR III期试验患者报告结局的分析

2025-02-190
PREAI
Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study

三药耐药多发性骨髓瘤(MM)患者中Cevostamab的生物标志物相关性及临床活性:这些患者已接受≥1种既往B细胞成熟抗原(BCMA)靶向双特异性抗体(BsAb);结果来自I/II期CAMMA 2研究

BLOOD
IF23.1
2024-11-050
PRE
Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) Analysis

澳大利亚和新西兰(ANZ)多发性骨髓瘤首次复发后的治疗:治疗模式和结局:一项ANZ骨髓瘤及相关疾病登记研究(ANZ MRDR)分析

BLOOD
IF23.1
2024-11-050
PRE